TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21617110

Group type: EXPERIMENTAL
Intervention: Bedtime treatment with ≥1 hypertension medications
Number of subjects: 448

Group type: COMPARATOR
Intervention: Conventional therapy (all medications ingested in the morning)
Number of subjects: 448
Study: 19471029

Group type: EXPERIMENTAL
Intervention: Coordinated care (intervention group)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 490
Study: 16501287

Group type: EXPERIMENTAL
Intervention: Thrombectomy with Mt-PA pre-administration (group T)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thrombectomy alone (group N)
Number of subjects: 44
Study: 14629070

Group type: EXPERIMENTAL
Intervention: Ultrasound‐assisted liposuction (UAL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical lipectomy
Number of subjects: 40
Study: 10792199

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9487417

Group type: EXPERIMENTAL
Intervention: Breastfeeding training for community health workers
Number of subjects: 0
Study: 7690046

Group type: EXPERIMENTAL
Intervention: Intelligent dosing system (IDS) for FK506
Number of subjects: 147
Study: 2876122

Group type: EXPERIMENTAL
Intervention: Prolonged continuous treatment with propranolol and other anti-arrhythmic drugs
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group treated in local outpatient clinics
Number of subjects: 329
Study: 30158072

Group type: EXPERIMENTAL
Intervention: Amlodipine-based treatment
Number of subjects: 8580

Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 8580

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 8580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8580

Group type: EXPERIMENTAL
Intervention: Non-LLA group (no lipid-lowering treatment) with amlodipine
Number of subjects: 8580

Group type: COMPARATOR
Intervention: Non-LLA group (no lipid-lowering treatment) with atenolol
Number of subjects: 8580
Study: 28659038

Group type: EXPERIMENTAL
Intervention: Joint treatment (fluoxetine + CBT)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Single active treatment (fluoxetine or CBT)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 195
Study: 24024528

Group type: EXPERIMENTAL
Intervention: Reading a text about genetic etiology of homosexual sexual orientation
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Reading a text about environmental etiology of homosexual sexual orientation
Number of subjects: 190

Group type: COMPARATOR
Intervention: Traditional opposition to same-sex parenting
Number of subjects: 190
Study: 24093845

Group type: EXPERIMENTAL
Intervention: FFR-guided group
Number of subjects: 350

Group type: COMPARATOR
Intervention: Angiography-guided group
Number of subjects: 350
Study: 20199136

Group type: EXPERIMENTAL
Intervention: Mealtime pramlintide (PRAM) 120 microg fixed dose
Number of subjects: 112

Group type: COMPARATOR
Intervention: Titrated rapid-acting insulin analogs (RAIAs)
Number of subjects: 112
Study: 18251641

Group type: EXPERIMENTAL
Intervention: SRP + CHX
Number of subjects: 116

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 116
Study: 16627888

Group type: EXPERIMENTAL
Intervention: Infants with mildly abnormal general movements (GMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal GMs
Number of subjects: 0
Study: 12739832

Group type: EXPERIMENTAL
Intervention: GM-CSF (150 microg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GM-CSF (not specified dose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (Control Group)
Number of subjects: 61
Study: 11789263

Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood (ILIB) therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional medicine (CM)
Number of subjects: 75
Study: 9383258

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cetirizine 10 mg/day
Number of subjects: 20
Study: 8222794

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg twice daily for 7 to 14 days)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Cefixime (400 mg once daily for 7 to 14 days)
Number of subjects: 213
Study: 3899369

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 18
Study: 30370463

Group type: EXPERIMENTAL
Intervention: Challenging situation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control situation
Number of subjects: 110
Study: 29309090

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 64
Study: 26726885

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400mg every 8 hrs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 24193180

Group type: EXPERIMENTAL
Intervention: Active prewarming with a forced-air warmer connected to a prewarming suit (Group C)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Passive preoperative insulation with a commercial prewarming suit (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard preoperative insulation (Group A)
Number of subjects: 90
Study: 22267495

Group type: EXPERIMENTAL
Intervention: Intraoral drainage approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: External cervical approach
Number of subjects: 40
Study: 20445836

Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (MPH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 18983789

Group type: EXPERIMENTAL
Intervention: Bupivacaine with midazolam (30 ml of 0.5% bupivacaine with midazolam 50 microg x kg‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bupivacaine (30 ml of 0.5% bupivacaine)
Number of subjects: 50
Study: 16088231

Group type: EXPERIMENTAL
Intervention: MEMID regimen (mitoxantrone, VP16, methylglyoxal, ifosfamide and dexamethasone)
Number of subjects: 149

Group type: COMPARATOR
Intervention: CEOP regimen (cyclophosphamide, epirubicin, vincristine and prednisone)
Number of subjects: 149
Study: 12143030

Group type: EXPERIMENTAL
Intervention: Human patient simulator experience before clerkship examination (Group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Self-study before clerkship examination (Group II)
Number of subjects: 90
Study: 11074901

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (patient education, training for participation, self-monitoring of prothrombin time, guideline-based management of warfarin dosing)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 325
Study: 9307534

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Gemeprost
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 48
Study: 8315546

Group type: EXPERIMENTAL
Intervention: Meperidine 2 mg/kg (M)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low-dose meperidine 1 mg/kg and diazepam 0.1 mg/kg (M low+D)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High-dose meperidine 2 mg/kg and diazepam 0.1 mg/kg (M high+D)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg/kg (D)
Number of subjects: 71
Study: 15791756

Group type: EXPERIMENTAL
Intervention: Experimental interviewing behaviors
Number of subjects: 0
Study: 30368429

Group type: EXPERIMENTAL
Intervention: Dynamic gait analysis
Number of subjects: 25

Group type: COMPARATOR
Intervention: Stationary gait analysis
Number of subjects: 25
Study: 27247843

Group type: EXPERIMENTAL
Intervention: Psychotherapy (active-comparator)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Psychotherapy (placebo-controlled)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Medication (active-comparator)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Medication (placebo)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Medication (medication)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Psychotherapy (psychotherapy)
Number of subjects: 615
Study: 25591522

Group type: EXPERIMENTAL
Intervention: Sermion (nicergoline)
Number of subjects: 880
Study: 22460061

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No preimplantation genetic screening (PGS)
Number of subjects: 101
Study: 20497949

Group type: EXPERIMENTAL
Intervention: Geriatric Depression Score (GDS) > or = 6
Number of subjects: 2656

Group type: EXPERIMENTAL
Intervention: Each additional GDS point at baseline
Number of subjects: 2656
Study: 18771363

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Scaling and root planing alone (control)
Number of subjects: 24
Study: 16227473

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 12566494

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 2 mg Cu/d for 6 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Basal diet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Basal diet supplemented with 1.0 mg Cu/d during equilibration
Number of subjects: 17
Study: 10385496

Group type: EXPERIMENTAL
Intervention: Single-dose ascorbic acid (2 g PO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Long-term ascorbic acid (500 mg/d)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 8909308

Group type: EXPERIMENTAL
Intervention: TF + N‐CWS (n = 41)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (surgery only) (n = 41)
Number of subjects: 82
Study: 1872141

Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 397

Group type: COMPARATOR
Intervention: Pretreatment group
Number of subjects: 397
Study: 31119466

Group type: EXPERIMENTAL
Intervention: IP6 (600 mg twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 28223407

Group type: EXPERIMENTAL
Intervention: Statin therapy in high genetic risk group
Number of subjects: 4910

Group type: EXPERIMENTAL
Intervention: Statin therapy in all others
Number of subjects: 4910

Group type: EXPERIMENTAL
Intervention: Meta-analysis of WOSCOPS, ASCOT, and JUPITER
Number of subjects: 4910

Group type: EXPERIMENTAL
Intervention: Polygenic risk score increase
Number of subjects: 4910
Study: 25879821

Group type: EXPERIMENTAL
Intervention: acute moderate physical activity for 30 min
Number of subjects: 50

Group type: COMPARATOR
Intervention: sedentary activity for 30 min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: acute moderate physical activity
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: positive parenting
Number of subjects: 50
Study: 23348636

Group type: EXPERIMENTAL
Intervention: Mericitabine 500 mg BID for 12 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mericitabine 1000 mg BID for 8 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mericitabine 1000 mg BID for 12 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo BID for 12 weeks + Peg-IFNα-2a/RBV
Number of subjects: 0
Study: 21331518

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 19
Study: 19297102

Group type: EXPERIMENTAL
Intervention: 1 mg 17‐beta estradiol daily and 0.35 mg norethindrone 3 days/week
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 17989859

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (50 g daily for 3 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 74
Study: 15381516

Group type: EXPERIMENTAL
Intervention: Manipulative therapy (up to 6 treatment sessions in a 12-week period)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 150
Study: 11378603

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (loading bolus of 300 mg followed by a continuous infusion of 1.5 mg.kg‐1.hr‐1 until the second postoperative day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 40
Study: 9643403

Group type: EXPERIMENTAL
Intervention: Abnormal Resistance Index (RI)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Bilateral diastolic notch
Number of subjects: 78

Group type: COMPARATOR
Intervention: Unilateral notch
Number of subjects: 78
Study: 8078656

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with vasopressin 25 IU% and noradrenaline bitartrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other three lidocaine solutions (not specified)
Number of subjects: 0
Study: 2676654

Group type: EXPERIMENTAL
Intervention: 40 mg/day lovastatin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 1500 mg/day clofibrate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 775086

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 31759901

Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs in advance care planning (ACP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care by control group GPs
Number of subjects: 140
Study: 30577971

Group type: EXPERIMENTAL
Intervention: MULTIPLE (8 trip-like gait perturbations)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SINGLE (1 trip-like gait perturbation)
Number of subjects: 24
Study: 26561424

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5%, 2%, and 5%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane (decreasing concentration order)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane (increasing concentration order)
Number of subjects: 20
Study: 25973909

Group type: EXPERIMENTAL
Intervention: ABT-089 (5, 10, 15, 20, 30, or 35 mg once daily)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study: 23806929

Group type: EXPERIMENTAL
Intervention: Digital animation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 32
Study: 21482337

Group type: EXPERIMENTAL
Intervention: Simple aspiration
Number of subjects: 400

Group type: COMPARATOR
Intervention: Chest tube drainage
Number of subjects: 400
Study: 18639301

Group type: EXPERIMENTAL
Intervention: Air charged catheter
Number of subjects: 64

Group type: COMPARATOR
Intervention: Microtip catheter
Number of subjects: 64
Study: 16504165

Group type: EXPERIMENTAL
Intervention: Tailor-made program addressing biopsychosocial factors
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care based on a pain contingent basis
Number of subjects: 126
Study: 12628866

Group type: EXPERIMENTAL
Intervention: Somnosmart (Weinmann; Hamburg, Germany)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Autoset (Resmed; North Ryde, Australia)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of both devices
Number of subjects: 16
Study: 10960046

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GTN (0.5 microg/kg per minute for 20 min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GTN
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls (n=16)
Number of subjects: 16
Study: 9108851

Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 1288902

Group type: EXPERIMENTAL
Intervention: Fentanyl, 2.5 micrograms.kg‐1
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fentanyl, 5 micrograms.kg‐1
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fentanyl, 10 micrograms.kg‐1
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 29
Study: 3876031

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g every four hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cimetidine (2 g intravenously)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antacids (every two hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg intravenously daily)
Number of subjects: 100
Study: 29091470

Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (200 mg caffeine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (noncaffeinated chewing gum)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (200 mg caffeine) in low habitual caffeine consumers (<40 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (noncaffeinated chewing gum) in low habitual caffeine consumers (<40 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeinated chewing gum (200 mg caffeine) in moderate/high habitual caffeine consumers (>130 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (noncaffeinated chewing gum) in moderate/high habitual caffeine consumers (>130 mg/day)
Number of subjects: 18
Study: 27046296

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Comparison group (looking at their paretic limb)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (mirror therapy and comparison)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (per protocol analyses)
Number of subjects: 90
Study: 24725910

Group type: EXPERIMENTAL
Intervention: Shared decision making intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 58
Study: 23790113

Group type: EXPERIMENTAL
Intervention: Closed-cell stents
Number of subjects: 96

Group type: COMPARATOR
Intervention: Open-cell stents
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Symptomatic patient group
Number of subjects: 96
Study: 20798909

Group type: EXPERIMENTAL
Intervention: Guideline-based care
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 19096961

Group type: EXPERIMENTAL
Intervention: 1-month stay at a wellness centre focusing on diet, exercise and stress management
Number of subjects: 200

Group type: COMPARATOR
Intervention: 30-60 min of oral and written information on lifestyle intervention
Number of subjects: 200
Study: 15826846

Group type: EXPERIMENTAL
Intervention: High frequency rTMS (17 Hz)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 71
Study: 14737792

Group type: EXPERIMENTAL
Intervention: Tokusou Rebase Fast Set
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coe Kooliner
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Total Hard
Number of subjects: 10

Group type: COMPARATOR
Intervention: All materials
Number of subjects: 10
Study: 10758049

Group type: EXPERIMENTAL
Intervention: Magnetic resonance coronary angiography (MRCA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: X-ray coronary angiography
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of MRCA and x-ray coronary angiography
Number of subjects: 25
Study: 8820204

Group type: EXPERIMENTAL
Intervention: Trained to plan, write, and revise opinion essays; used interactive dialogues for planning and revising.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Trained participants
Number of subjects: 38

Group type: COMPARATOR
Intervention: Untrained control group
Number of subjects: 38
Study: 1601688

Group type: EXPERIMENTAL
Intervention: Nonprescription firm-support pantyhose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nonprescription sheer-support pantyhose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Follow-up after one year
Number of subjects: 30
Study: 4015326

Group type: EXPERIMENTAL
Intervention: Cyproheptadine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30871921

Group type: EXPERIMENTAL
Intervention: Ranolazine + ACEI/ARB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + ACEI/ARB
Number of subjects: 0
Study: 28528818

Group type: EXPERIMENTAL
Intervention: Patellar tendon vibration
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition (vibrator turned off)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Femoral nerve stimulation (2×motor threshold)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Post-vibration recovery
Number of subjects: 27
Study: 25725502

Group type: EXPERIMENTAL
Intervention: Sunlight intervention trial
Number of subjects: 31
Study: 23519576

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 600 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 40
Study: 21677639

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 19388994

Group type: EXPERIMENTAL
Intervention: Serous-lined extramural tunnel
Number of subjects: 60

Group type: COMPARATOR
Intervention: T-limb ileal procedure
Number of subjects: 60
Study: 16430561

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 12 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine 17 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 90
Study: 15262911

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 13